Now heres a nice little earner..

Noticed Regen therapeutics rose upto 6p 2weeks ago...if anyone missed em, heres a good chance to get in at under 3p...(I missed em at the time...!)

I bought in at 2.75p today to see where they go in the weeks to come...

Jules99.

Still quiet on this board despite all the activity on this one of late. up 12% early in the day with much heavy buying afterwards which hasn't pushed price further yet but wait 'til monday. Todays wasthe highest trade volume for some months.

There was a placing at 2.75p when the price only stood at 3p which indicated things were about to happen. The recent buys have all but soaked up that placing and today the directors were granted options exercisable at 6p when at close of play the price stood at 3.38P so you can see where they think the price is headed.

The product Collostrinin is due to have a favourable article in a respected medical journal later this month and in the words of the chairman (or roughly) "this will be a very different company by the end of the year." We suspect this means a licensing deal in preparation for phase 3 trials of the pharmaceutical product whilst advances are made towards marketing a nutraceutical product in the USA.

Regen is an exciting place to be at the moment.DYOR

Surely there must be some other holders here what are your thoughts?

See Fortune Oil thread.

Grandma - I was so excited to see someone else here and eagerly took your advice but could see nothing there relating to RGT! Perhaps I missed something or possibly you were just generously giving us the benefit of a tip however with RGT there is huge potential and that's just beginning to take off. I'd prefer to catch the start of the wave than the crest - but thanks anyway.

Gantenbrink sorry took so long to reply- was trying yesterday late when Grandpa's computer went off-line = big trouble. "What have you done?" etc etc-took all day to sort. Posting 61 on the Fortune Oil thread has another Regen enthusiast so I thought to point out to Regen holders.Alas my original shares are very otm but have averaged down. Hope you are right re huge potential.

I have more than just a passing interest in this and wish good test results. Trading's been around the 3p level for quite some time, but I am v.encouraged by Gantenbrink's comments on Directors share options. My concern is whether the money might run out before potential is realised or a potential partner has been secured. Seems a European partner is more likely, but when might this happen??? Will be on board by early March, just waiting for a decent buying opportunity. Good luck to all those holding

Danmatt/ Grandma - sorry been away for a few days - can highly recommend Eurostar to Brussels - my first time and we were there before we would normally have taxied down a runway for take off.

Anyway enough of my trip... with regard to money running out I believe they now have over 1.5 m in the bank Losses ( therefore expenses as no income) last year were about 1.9 mill so with falling costs they should have a year or so in reserve.

Would hope for news of the favourable article about phase 2 in the trade press within the near future poss next week or so and that might bring about a new spurt of activity.

Good luck if you hold or join.

Nice to be proved right as the RNS today about the phase 2 article did indeed produce activity (Up over 30% at one point). Profit taking pulled it back but shows how quickly this one can take off and each time it raises the threshold. According to Percy Lomax he is actively seeking a licensing partner to take us through to phase 3 by end of 2004. When that happens there will be no looking back so glad to have established my holding at these levels.

Copied from elsewhere and thanks to Buzzno7 who found this:-

Press Release Source: ReGen Therapeutics Plc; Sky Investor Relations


ReGen Therapeutics Retains Sky Investor Relations to Raise Awareness in the U.S.
Thursday March 18, 10:52 am ET


NEW YORK, March 18 /PRNewswire/ -- United Kingdom-based ReGen Therapeutics Plc (AIM: RGT), a biotechnology company that is developing a treatment for Alzheimer's disease, announced today that it has retained Wall Street-based Sky Investor Relations to raise its visibility in the U.S.
ReGen Therapeutics has had a U.S. presence through its scientific research and development activities, which are being conducted at the University of Texas Medical Branch in Galveston, Texas. ReGen's principal drug, Colostrinin(TM), is being developed as a treatment for Alzheimer's disease. Colostrinin(TM) is patented in four countries including the Untied States. ReGen has been publicly traded on the AIM market, a division of the London Stock Exchange, since 2000.

"We anticipate that the U.S. will be a primary market for our Alzheimer's drug. With the support of Sky IR we hope to increase recognition of our company and Colostrinin(TM) amongst the American medical community, trade media, and U.S.-based financial professionals," stated ReGen Therapeutics Executive Chairman, Mr. Percy Lomax.

"We are very excited to represent ReGen Therapeutics to our extensive network of business professionals and journalists in the healthcare field. Alzheimer's disease plagues an estimated 10 million people in industrialized nations alone and therefore ReGen and its development of an Alzheimer's treatment warrant further attention from the healthcare community in the U.S.," stated Ms. Laurel Moody, President of Sky Investor Relations. ReGen Therapeutics will be hosting an introductory presentation in New York City on March 24, 2004 at the Plaza Hotel. Those interested in attending the presentation may contact Ms. Christine Petraglia of Sky IR at 212-440-5000.

About ReGen Therapeutics Plc

ReGen Therapeutics is a biotechnology company that develops and explores the use of Colostrinin(TM), for the treatment of Alzheimer's disease and other neurological disorders. Colostrinin(TM) is based on colostrum derived from sheep and is the mammal's first milk after the birth of an offspring. The Company is currently pursuing a dual-track commercialization strategy through the development and marketing of prescription Colostrinin(TM), as well as a Colostrinin(TM)-based nutraceutical product.

About Sky Investor Relations

Sky Investor Relations is a leading Wall Street-based investor and public relations firm servicing the needs of micro and small-cap publicly traded companies. Sky IR has offices in London and Los Angeles, in addition to its headquarters in New York City. Through investment community contacts, media placements and corporate positioning and communications, Sky IR raises the visibility of its clients and supports enhanced shareholder value. Sky IR is a subsidiary of Sky Venture Capital.

Neither ReGen nor any of its existing shareholders is offering any securities for sale in the United States. This press release is not an offer to sell or a solicitation of offers to buy any securities in the United States. ReGen's securities are not registered under the U.S. Securities Act of 1933.

Statements in this press release other than statements of historical fact, including statements regarding the company's plans, beliefs, and estimates as to projected market size are "forward-looking statements." Such statements are subject to certain risks and uncertainties, and actual results could differ materially from expected results. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements